Document text
Principal Investigator: Charles Bix Shoemaker
Organization: TUFTS UNIVERSITY BOSTON
Fiscal Year: 2023
Award: $247,500
Funding agency: National Institute of Allergy and Infectious Diseases
Schistosomes are parasitic flatworms that cause a chronic, debilitating disease afflicting
>200 million people in >70 countries. Since there are limited anti-schistosome drugs
available and since these is no vaccine to prevent infection, we aim here to generate and
test nanobody-based immunotherapeutics targeting essential surface-exposed parasite
proteins as a novel intervention to control schistosomiasis. Nanobodies (camelid single-
domain antibodies or VHHs) are small, versatile binding agents that can be multimerized
for enhanced activities and delivered effectively by formulated mRNA. We have identified
and characterized three S. mansoni tegumental ectoenzymes (SmNPP5, SmT-AChE,
SmCA) that represent novel molecular targets for intervention to treat schistosomiasis.
Each of the three enzymes is exposed at the host parasite interface and each is essential
for the parasite to infect its vertebrate host. We aim to generate nanobodies that inhibit the
function of these three target enzymes (each enzyme has been purified in functional form
in CHO-S cells). The small size, stability to heat and pH extremes, low immunogenicity,
and facility to express as multimers with enhanced activities, makes VHHs preferred
therapeutic agents. We exploit advances in RNA therapeutics as our strategy to efficiently
and economically deliver sustained levels of serum VHH-based therapeutics. Our overall
goal is to generate a simple, practical, and potent anti-schistosome therapeutic that
curtails disease at all stages of infection. In sum, we have identified new, well
characterized, accessible and rational targets for anti-schistosome intervention, and
we incorporate an innovative, novel, cutting-edge approach to control
schistosomiasis. We have assembled a strong team and have on-hand all reagents and
tools necessary to ensure the success of this project. Our data will act as a proof of
principle supporting an approach that, in the longer term, could form the basis of a new
therapeutic for human schistosomiasis, as well as for other debilitating helminth diseases.
Terms: <Acetylcholine Hydrolase><Acetylcholinesterase><Ache><Adolescent><Adolescent Youth><Affinity><Alpaca><Bilharzia><Bilharziasis><Binding><Biochemical><Blood Serum><CHO Cells><Carbonate hydro-lyase><Carbonic Anhydrases><Chinese Hamster Ovary Cell><Chronic><Clinical Trials><Country><Data><Development><Disease><Disorder><Drug Kinetics><Drug usage><Drugs><Ensure><Enzyme Gene><Enzymes><Family><Fc domain><Flatworms><Gene Transcription><Genetic Transcription><Goals><Hand><Helminths><Human><Immunize><Immunotherapeutic agent><In Vitro><Infection><Infection Control><Infection prevention><Intervention><Intervention Strategies><Laboratory Study><Length of Life><Libraries><Life><Link><Longevity><Lymphatic cell><Lymphocyte><Lymphocytic><Medication><Messenger RNA><Methods><Mice><Mice Mammals><Modern Man><Molecular><Molecular Interaction><Molecular Target><Murine><Mus><Non-Polyadenylated RNA><PZQ resistance><PZQ resistant><Parasites><Parasitic Worms><Persons><Phage Display><Pharmaceutic Preparations><Pharmaceutical Preparations><Pharmacokinetics><Phosphodiesterases><Platyhelminthes><Platyhelminths><Post-Transcriptional Gene Silencing><Posttranscriptional Gene Silencing><Prasiquantel><Praziquantel><Praziquantel resistance><Praziquantel resistant><Prevent infection><Proteins><Publishing><Quelling><RNA><RNA Expression><RNA Gene Products><RNA Interference><RNA Silencing><RNA based therapeutics><RNA based therapy><RNA therapy><RNAi><Reagent><Recombinants><Resistance to Praziquantel><Ribonucleic Acid><S mansoni><S. mansoni><Schistosoma><Schistosoma mansoni><Schistosomatidae><Schistosome><Schistosomiasis><Sequence-Specific Posttranscriptional Gene Silencing><Series><Serum><Surface><Technology><Testing><Therapeutic><Therapeutic Agents><Therapeutic Intervention><Transcription><Tropical Disease><Vaccines><World Health Organization><acetylcholine acetylhydrolase><blood fluke><bone><carbonate dehydratase><choline esterase I><developmental><dimer><drug use><drug/agent><hands><immune drugs><immune-based therapeutics><immunogenicity><immunologic therapeutics><immunotherapeutics><immunotherapy agent><improved><in vivo><innovate><innovation><innovative><intervention therapy><interventional strategy><juvenile><juvenile human><life span><lifespan><lymph cell><mRNA><nanobodies><nanobody><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><phosphoric diester hydrolase><prevent><preventing><pyrophosphatase><response><sdAb><single domain antibodies><success><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic RNA><tool>